S

Syneos Health

Global provider of integrated clinical-to-commercial services

Senior Cybersecurity Engineer - Exposure Management

Full-Time
No salary listed
Senior
Hyderabad, Telangana, India
Hybrid
Cybersecurity

About the job

Requirements
  • 7+ years of cybersecurity experience, including significant hands-on experience in vulnerability management, exposure management, threat-informed defense, cloud security, infrastructure security, or security operations engineering.
  • Demonstrated experience operating or maturing a risk-based vulnerability management, exposure management, or Continuous Threat Exposure Management (CTEM)-aligned program.
  • Proven ability to lead cross-functional remediation initiatives without direct reporting authority.
  • Strong understanding of CTEM lifecycle concepts: scoping, discovery, prioritization, validation, and mobilization.
  • Experience correlating asset context, exploitability, threat intelligence, business criticality, control state, and remediation feasibility into defensible prioritization decisions.
  • Hands-on experience with vulnerability and exposure platforms and related ecosystem tools, including scanners, endpoint detection and response and extended detection and response, configuration management databases and cyber asset attack surface management, cloud security platforms, identity and access management, attack surface management and external attack surface management, information technology service management, security information and event management and security orchestration, automation and response, and threat intelligence sources.
  • Experience with service-level agreement models, exception workflows, compensating controls, risk acceptance, residual risk reporting, and validated closure.
  • Ability to communicate exposure and residual risk clearly to engineering, operations, security leadership, and non-technical stakeholders.
  • Working knowledge of automation, application programming interfaces, scripting, or data analysis methods used to improve exposure management workflows.
Responsibilities
  • Help define, implement, and continuously improve the CTEM lifecycle across scoping, discovery, prioritization, validation, and mobilization.
  • Translate exposure management strategy into repeatable operating processes, decision criteria, governance routines, and measurable outcomes.
  • Identify maturity gaps across asset coverage, signal quality, prioritization, validation, remediation ownership, exception handling, and executive reporting.
  • Partner with security, infrastructure, cloud, endpoint, identity, application, architecture, and business teams to establish shared accountability for exposure reduction.
  • Drive structured exposure review cycles that move the organization from vulnerability reporting to validated, risk-based remediation and measurable risk reduction.
  • Engineer and operate exposure management capabilities across infrastructure, cloud, endpoints, identity, applications, and third-party surfaces.
  • Maintain and enhance tooling that aggregates vulnerability data, asset context, threat intelligence, and exploitability signals.
  • Ensure accurate asset discovery, coverage validation, and telemetry quality across the enterprise attack surface.
  • Drive risk- and threat-informed prioritization beyond Common Vulnerability Scoring System scoring.
  • Incorporate exploit intelligence, threat actor activity, asset criticality, and compensating controls.
  • Partner with technology and business owners to translate exposure into remediation priorities.
  • Correlate exposure data with threat intelligence and adversary tactics, techniques, and procedures.
  • Support zero-day and emerging threat response through rapid exposure analysis.
  • Define and maintain CTEM outcome metrics, including exposure reduction, risk burndown, validated closure rate, service-level agreement adherence, exception aging, reintroduced exposure rate, coverage gaps, telemetry freshness, owner assignment accuracy, and remediation cycle time.
  • Build executive, operational, engineering, and audit views that explain risk, accountability, trend, residual exposure, and progress against maturity goals.
  • Convert technical findings into business-relevant narratives that support prioritization, funding, architecture decisions, and remediation mobilization.
  • Identify recurring exposure patterns and recommend control, architecture, automation, or process improvements.
  • Lead exposure reduction initiatives across teams without direct reporting authority, using data, risk rationale, business impact, and clear decision records to drive alignment.
  • Facilitate remediation planning across infrastructure, cloud, endpoint, application, identity, security operations center, governance, risk, and compliance, and business stakeholders.
  • Build consensus on ownership, prioritization, compensating controls, exception paths, and remediation timelines.
  • Escalate systemic blockers with clear options, residual risk framing, and recommended decisions.
  • Mentor analysts and engineers while raising the overall maturity of exposure management practices.
  • Collaborate with subject matter experts to define mitigation strategies and compensating controls.
  • Provide leadership with clear, defensible views of exposure and residual risk.
  • Provide operational guidance to and oversight of managed server provider technicians.
Desired Qualifications
  • Experience implementing or significantly maturing a CTEM-style program in a large enterprise.
  • Familiarity with Exploit Prediction Scoring System, Cybersecurity and Infrastructure Security Agency Known Exploited Vulnerabilities, Stakeholder-Specific Vulnerability Categorization-style decisioning, Common Vulnerability Scoring System version 4 environmental and threat context, exploit telemetry, ransomware intelligence, and threat actor tactics, techniques, and procedures mapping.
  • Experience with attack-path analysis, adversarial exposure validation, breach and attack simulation, red-team or penetration-testing integration, or control validation.
  • Experience applying artificial intelligence or machine learning to exposure management, including summarization, deduplication, risk explanation, ticket enrichment, remediation recommendation drafting, or executive reporting.
  • Knowledge of artificial intelligence governance, human-in-the-loop controls, model and data protection, auditability, and safe automation design.
  • Experience integrating exposure workflows with ServiceNow or equivalent information technology service management platforms.
  • Experience with cloud-native exposure management across Amazon Web Services, Microsoft Azure, Google Cloud Platform, containers, Kubernetes, infrastructure as code, software as a service, identity, and application security findings.
  • Industry certifications such as Certified Information Systems Security Professional, Global Information Assurance Certification, Offensive Security Certified Professional, cloud security, or relevant offensive or defensive security credentials.

About the company

Syneos Health provides end-to-end biopharmaceutical solutions across the clinical-to-commercial spectrum. It helps biopharma companies, healthcare organizations, and investors by offering specialized expertise, insights, and technology-enabled services to move therapies faster to patients. Its offerings include Kinetic, a modern omnichannel customer engagement platform that uses targeting and analytics to coordinate nationwide healthcare communications, and Syneos One, an asset development approach that aligns strategy and execution from early concept through commercialization. The company uses AI and advanced tech to improve performance and reduce risk in drug development and market delivery. Its goal is to be a trusted partner that accelerates therapy development and delivery by combining scientific know-how with integrated, data-driven services.

Company Size

10,001+

Company Stage

IPO

Headquarters

Morrisville, North Carolina

Founded

1985

Get referred to Syneos Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • KAI partnership on April 30, 2026 expands commercial intelligence for U.S. pharma launches.
  • Syneos says Causaly cut study-design insight time roughly 50% in 2026.
  • Databricks reduced source-data review from days to hours, speeding trial interventions.

What critics are saying

  • March 31, 2026 Kempen discovery keeps securities-fraud claims alive over backlog reporting.
  • Syneos Italy announced 49 layoffs on March 25, 2026, signaling operating pressure.
  • A sustained data-integrity finding in Kempen would damage sponsor trust and trigger defections.

What makes Syneos Health unique

  • Syneos combines clinical development and commercialization under one roof, unlike pure-play CROs.
  • August 18, 2026 AI stack spans Causaly, Databricks, and Microsoft across workflows.
  • More than 280 Microsoft Copilot agents give Syneos broad internal automation depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Employee Stock Purchase Plan
  • Flexible Work Hours
  • Paid Vacation
  • Paid Sick Leave
  • Remote Work Options

Company News

TransportTalk
Aug 31st, 2026
Teletrac Navman appoints Sara Epstein to senior leadership role.

Teletrac Navman appoints Sara Epstein to senior leadership role. Reading Time: 2 mins read Teletrac Navman has appointed Sara Epstein as chief legal and administrative officer as the connected mobility business enters its next phase of growth. Epstein brings more than 20 years of legal and executive leadership experience across sectors including healthcare, life sciences, pharmacy and logistics. She will oversee Teletrac Navman's legal, compliance, data privacy and governance functions, along with People and Culture and Health and Safety. Epstein was previously chief legal officer at pharmacy benefits company RxBenefits and executive vice president and deputy general counsel at Syneos Health, where she led a global team responsible for legal and privacy services. She has also held senior legal roles at Cotiviti Holdings and BlueLinx Holdings and was an associate at international law firm Jones Day. Teletrac Navman President and chief executive Alain Samaha says Epstein's experience will support the company's strategic and growth plans. "Sara brings a powerful combination of legal acumen, business judgment and executive leadership that will help accelerate our strategic initiatives and support our long-term growth," Samaha says. "Her experience leading global teams and navigating complex business environments will be instrumental as we continue to drive innovation, strengthen our customer relationships and execute on our growth ambitions. We're thrilled to welcome her to the team." The appointment follows Teletrac Navman's acquisition by Respida Capital earlier this year and a series of product developments, including the launch of Energy Hub within its TN360 fleet management platform and the company's Electronic Braking Performance Monitoring System. "I'm excited to join Teletrac Navman at such an important time in the company's evolution," Epstein says. "The organisation has a strong foundation, a talented global team, and a clear vision for growth. I look forward to working across the business to support our strategic priorities and contribute to the next chapter of Teletrac Navman's success." Epstein holds a Juris Doctor from Tulane University Law School and a bachelor's degree from Tufts University.

HR TODAY
Aug 26th, 2026
Madhuri Raya joins Syneos Health as Global Head, AI & Engineering and Technology Capability Center.

Madhuri Raya joins Syneos Health as Global Head, AI & Engineering and Technology Capability Center. Hyderabad, Telangana, India, August 2026 - Syneos Health has appointed Madhuri Raya as Global Head, AI & Engineering and Technology Capability Center, strengthening its technology leadership as the organisation accelerates its AI-enabled strategy. In her new mandate, Raya will focus on scaling engineering capabilities behind Syneos Health's growing AI ecosystem and helping translate technology innovation into practical solutions for biopharmaceutical development. Raya brings more than two decades of experience across software engineering, product engineering, cloud-native technologies, AI/ML-enabled solutions and global engineering leadership. She joins Syneos Health after a long tenure with Optum, where she most recently served as Vice President of Software Engineering. During more than eight years with the organisation, she progressed through senior technology leadership positions, including Director of Product Engineering and Senior Director - Product Engineering. Before Optum, Raya spent more than five years with UnitedHealth Group, serving as Engineering Manager and subsequently Senior Engineering Manager. These roles added to her experience in leading engineering organisations within the healthcare ecosystem and managing increasingly complex technology responsibilities. Earlier in her career, Raya spent more than a decade with the Robert Bosch Research and Technology Center. She worked initially as a Software Engineer before progressing to Senior Research Engineer, a position she held for more than seven years. This foundation in software engineering and research, followed by leadership roles across healthcare technology and product engineering, has shaped a career spanning technical innovation and large-scale engineering management. At Syneos Health, Raya joins at a time when the company is expanding the role of AI and technology across its operations. Her mandate will center on strengthening the engineering capabilities supporting this strategy, bringing together AI, engineering and technology delivery to improve agility, precision and intelligence in addressing customer challenges. She is an alumna of the Birla Institute of Technology and Science, Pilani (BITS Pilani). Syneos Health is a fully integrated biopharmaceutical solutions organisation focused on accelerating customer success. The company combines clinical, commercial and real-world insights to help address evolving market needs and support the delivery of therapies to patients. Its professionals bring together knowledge of patient and physician behaviours, market dynamics, technology and advanced business practices. Syneos Health positions technology and cross-functional expertise as important enablers in helping customers advance the development and commercialisation of therapies.

Applied Clinical Trials
Aug 19th, 2026
Syneos Health expands AI ecosystem with three new platform partnerships.

Syneos Health expands AI ecosystem with three new platform partnerships. New collaborations with Causaly, Databricks, and Microsoft anchor a broader push to embed artificial intelligence directly into clinical trial decision-making and operational workflows. "When technology is applied precisely at critical decision points, teams can anticipate risk earlier to accelerate development." Syneos Health has announced the continued expansion of its artificial intelligence (AI) ecosystem, detailing three platform partnerships designed to embed AI into core clinical development workflows.[1] The three partnerships each target a distinct layer of the clinical development stack. Through a new collaboration with Causaly, Syneos is applying agentic, evidence-based scientific reasoning to accelerate protocol strategy development, feasibility planning, and competitive trial intelligence. Causaly's platform surfaces evidence from a proprietary knowledge graph combining biomedical research and commercial insights. According to the company, the integration has reduced the time it takes to derive insights for study strategy and design by approximately 50%. The partnership with Databricks focuses on the data infrastructure layer. By leveraging the Databricks Data and AI Platform, Syneos has developed a near real-time view of clinical operations that reduces the time from source data capture to review-ready insight from days to hours, enabling faster intervention and more efficient trial execution. The Microsoft collaboration, which builds on a relationship that began in 2023, extends AI adoption through productivity and workflow tools. Syneos has used Microsoft Power Apps and other tools to develop more than 280 agents that integrate with Microsoft 365 Copilot to streamline workflows and support faster decision-making across the organization. "When technology is applied precisely at critical decision points, teams can anticipate risk earlier to accelerate development," said Mike Montello, chief digital and information officer at Syneos Health, in a company press release. Together, the three partnerships are designed to create what Syneos Health describes as a unified intelligence environment - connecting operational, clinical, and real-world data across the development lifecycle. The company noted that all capabilities are deployed with human oversight and governance to ensure responsible use in regulated environments. A broader conversation about AI and site readiness. The Syneos announcement reflects a pattern Applied Clinical Trials has been tracking closely: sponsor investment in AI is accelerating, but questions about how that technology reaches sites - and whether it actually fits their workflows - remain unresolved. In a recent with ACT, Liz Beatty, co-founder and chief strategy officer at Inato, addressed that tension directly.[2] Beatty argued that the industry has consistently made the mistake of building technology for sponsors rather than for sites. "We need to stop, and instead think: how can I enable sites to use this technology to become more efficient and effective in clinical trials, which then helps my trial and my company - not the other way around," she said. On where AI is delivering measurable enrollment impact, Beatty pointed to real-time patient data as the most significant shift. Rather than relying on feasibility questionnaires and sponsor-discounted estimates, AI tools can now identify which specific patients at a given site currently meet study criteria. In a chronic obstructive pulmonary disease case study, than those that did not, and 100% of sites using the tool were able to successfully screen and enroll patients. Looking ahead, Beatty pointed to a structural shift she sees gaining momentum: sponsors moving away from trial-by-trial site planning toward program or cross-asset planning, building deeper site partnerships across multiple studies. This represents a dynamic that could meaningfully change how enrollment bottlenecks are addressed before a trial even begins. References

News Break! Middle East
Aug 18th, 2026
Syneos Health advances ai-powered clinical ecosystem to optimize trial performance and speed decision-making.

Syneos Health advances ai-powered clinical ecosystem to optimize trial performance and speed decision-making. Expanding set of partners and proprietary insights strengthens operational performance. MORRISVILLE, N.C., Aug. 18, 2026 (GLOBE NEWSWIRE) - Syneos Health(R), a leading fully integrated biopharmaceutical solutions organization, today announced the continued advancement of its AI ecosystem - a unified, enterprise approach that embeds artificial intelligence (AI) directly into the core of clinical development. By combining deep therapeutic expertise, healthcare professional intelligence and modern AI technologies, Syneos Health is helping sponsors navigate an increasingly complex development landscape. Grounded in decades of clinical and commercial experience, Syneos Health's differentiated AI approach focuses on integrating advanced capabilities into critical decision points across protocol design, feasibility, enrollment planning, site activation, monitoring and operational oversight. This enables teams to anticipate risk earlier, reduce friction across workflows and make faster, more informed decisions that improve study performance. "Our priority is AI that works inside the complexity of clinical trials. By combining advanced AI with a deep understanding of sites, physicians, patients and the operational dynamics that shape trial performance, we're unlocking new opportunities for speed, clarity and quality," said Mike Montello, Chief Digital and Information Officer, Syneos Health. "When technology is applied precisely at critical decision points, teams can anticipate risk earlier to accelerate development." Enterprise AI and Data Platforms Syneos Health is building a future ready ecosystem bringing together capabilities combining scientific expertise, connected data and evidence, and AI-enabled execution. This integrated approach creates a unified intelligence environment that enables faster, more informed decisions across the clinical development lifecycle. * Causaly - Syneos Health's new collaboration with Causaly applies agentic, evidence-based scientific reasoning to enable faster protocol strategy development, feasibility planning and competitive trial intelligence. Built specifically for the life sciences sector, Causaly's Agentic Research surfaces evidence from a proprietary knowledge graph combining biomedical research and commercial insights. By accelerating analysis of complex biomedical literature and emerging data, Syneos Health teams have reduced the time it takes to derive insights for study strategy and design by approximately 50%. * Databricks - Using Databricks enables Syneos Health to create a more powerful, unified intelligence environment that brings together operational, clinical and real-world data to advance modern clinical development. Leveraging the Databricks Data + AI Platform, Syneos Health has developed a continuous, near real-time view of clinical operations that reduces the time from source data capture to review-ready insight from days to hours, enabling faster intervention and more efficient trial execution. * Microsoft - Building on its long-standing collaboration that began in 2023, Syneos Health is driving AI adoption through its integration with Microsoft. Specifically, Syneos Health has used Microsoft Power Apps and other tools to develop more than 280 agents that integrate with Microsoft 365 Copilot to improve productivity, streamline workflows and support faster, more confident decision-making across the company. Complementing these foundational capabilities are frontier agentic AI solutions and proprietary Syneos Health insights embedded directly within clinical workflows. Together, they help improve predictability, reduce operational complexity, and drive more precise, scalable trial performance. These capabilities are deployed with strong human oversight and governance, ensuring responsible use in regulated environments. "What differentiates Syneos Health is our ability to redesign how clinical development decisions are made through the combination of scientific intelligence, connected evidence, operational expertise and AI-enabled execution across the development lifecycle," said Michael Brooks, Chief Operating Officer, Syneos Health. "By grounding AI in deep clinical expertise and real-world experience, we help sponsors reduce complexity, make better-informed decisions and ultimately deliver better outcomes for patients." About Syneos Health Syneos Health(R) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. News Break Middle East translate unique clinical, commercial and real world insights into outcomes to address modern market realities. News Break Middle East bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together News Break Middle East share diverse insights, use the latest technologies and apply advanced business practices to speed its customers' delivery of important therapies to patients. Syneos Health is powered by an authentic, inclusive and high-performance culture that cares for colleagues, customers, patients, communities and the environment. Press/Media Contact: Meg Byers Director, External Communications [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. News Break Middle East do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

MarketBeat
Aug 12th, 2026
Inovio Pharmaceuticals (NASDAQ:INO) releases quarterly earnings results, beats expectations by $0.15 EPS.

Inovio Pharmaceuticals (NASDAQ:INO) releases quarterly earnings results, beats expectations by $0.15 EPS. August 12, 2026 Key points. * Inovio beat earnings expectations: The company reported a quarterly loss of $0.07 per share, $0.15 better than the consensus estimate of a $0.22 loss. * INO-3107 remains on track for FDA review: The treatment's October 30, 2026 PDUFA date is intact, and Inovio is advancing launch preparations, though accelerated approval and final timing remain uncertain. * Funding remains a concern: Inovio ended the quarter with $36.7 million in cash and expects about $18 million in operational cash burn during the third quarter; a July equity offering is expected to fund operations into late Q1 2027, excluding additional capital raises. * Five stocks we like better than Inovio Pharmaceuticals. Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.15, FiscalAI reports. Here are the key takeaways from Inovio Pharmaceuticals' conference call: * Positive Sentiment: INO-3107's FDA review remains on track for the October 30, 2026 PDUFA date; late-cycle review and pre-licensure inspections are complete, with only one reported inspection observation that the company believes it has addressed. * Positive Sentiment: Inovio is advancing launch preparations for INO-3107, including label negotiations expected to begin in September, medical science liaison activities, and a commercialization agreement with Syneos Health. If approved, the company expects seven years of orphan-drug market exclusivity. * Negative Sentiment: The FDA has not yet indicated whether INO-3107 qualifies for accelerated approval, and feedback on the confirmatory-trial design remains outstanding. The company continues to characterize approval and launch timing as potential outcomes rather than assured results. * Negative Sentiment: Inovio ended the quarter with $36.7 million in cash, cash equivalents, and short-term investments, and expects approximately $18 million of operational net cash burn in Q3. July's $18.3 million equity offering extends funding into late Q1 2027 and through a potential launch, but the company noted that this projection excludes future capital raises. * Positive Sentiment: Partner ApolloBio reported positive pivotal Phase III results for VGX-3100 in cervical dysplasia, meeting its primary efficacy endpoint and supporting plans for a potential regulatory filing in China. Inovio also reported encouraging preclinical progress for its DPROT platform in hemophilia A and other rare diseases. Inovio Pharmaceuticals price performance. Inovio Pharmaceuticals stock traded up $0.00 during mid-day trading on Wednesday, hitting $0.77. 3,060,340 shares of the company were exchanged, compared to its average volume of 2,293,542. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.98. The company has a market capitalization of $63.35 million, a P/E ratio of -0.53 and a beta of 1.52. The business's 50 day simple moving average is $1.04 and its two-hundred day simple moving average is $1.31. Wall Street analyst weigh in. Several equities analysts recently issued reports on INO shares. Wall Street Zen cut Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Sunday, June 21st. HC Wainwright lowered their target price on Inovio Pharmaceuticals from $3.00 to $2.50 and set a "neutral" rating on the stock in a report on Monday, June 1st. Weiss Ratings upgraded Inovio Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 29th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $4.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $3.25. Discover more Track Market Trends Stock split calculator Earnings screener tool Institutional trading of Inovio Pharmaceuticals. A number of large investors have recently made changes to their positions in INO. Millennium Management LLC raised its position in shares of Inovio Pharmaceuticals by 468.7% in the third quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company's stock valued at $4,616,000 after buying an additional 1,625,653 shares during the last quarter. Vanguard Group Inc. boosted its position in Inovio Pharmaceuticals by 35.0% during the third quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company's stock worth $6,348,000 after acquiring an additional 703,727 shares during the last quarter. 683 Capital Management LLC acquired a new stake in Inovio Pharmaceuticals during the fourth quarter worth approximately $433,000. OMERS ADMINISTRATION Corp purchased a new stake in Inovio Pharmaceuticals in the 4th quarter worth approximately $388,000. Finally, Geode Capital Management LLC grew its stake in Inovio Pharmaceuticals by 40.7% in the 4th quarter. Geode Capital Management LLC now owns 769,356 shares of the biopharmaceutical company's stock worth $1,340,000 after acquiring an additional 222,609 shares during the period. Institutional investors and hedge funds own 26.79% of the company's stock. About Inovio Pharmaceuticals. Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats. Central to Inovio's platform is its SynCon(R) technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra(R) electroporation device, designed to enhance cellular uptake and expression of DNA vaccines. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Inovio Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list. While Inovio Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.